JOHN BROOKS: Open Payments
NPI 1609886530 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,529 in 68 payments from 16 companies in 2025. Trend: 2023 $287 · 2024 $1,275 · 2025 $1,529
Food & beverage: $1,529
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 13 | $218 |
| Sumitomo Pharma America, Inc. | 3 | $190 |
| Novartis Pharmaceuticals Corporation | 8 | $180 |
| Abbott Laboratories | 6 | $155 |
| PFIZER INC. | 7 | $154 |
| Lilly USA, LLC | 6 | $100 |
| SANOFI-AVENTIS U.S. LLC | 3 | $80 |
| Eisai Inc. | 3 | $76 |
| Exact Sciences Corporation | 3 | $71 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $61 |
Products named: GEMTESA, LEQVIO, FREESTYLE LIBRE 3, EVENITY, PREVNAR 20, TZIELD, Leqembi, MOUNJARO.
Industry payments across TX — which companies pay providers there.
